Uncategorized
Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that could shape the future of ADCs, protein degraders and KRAS-targeted therapies.